| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2971707 | The Journal of Heart and Lung Transplantation | 2010 | 7 Pages |
Abstract
In lung transplant recipients with BOS Stage 1, azithromycin treatment initiated before BOS Stage 2 was independently associated with a significant reduction in the risk of death. This finding supports the need for a randomized, controlled trial to confirm the impact of azithromycin on survival in lung transplant recipients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Raksha MD, Ramsey R. MD, Matthew R. MD, Elbert P. MD, Murali M. MD, Roger D. MD, MPH, Howard J. MD, Thalachallour BVSc, PhD, G. Alexander MD, Michael J. MD,